|
|
Office Locations:
|
400 Technology Square, Suite 101
Cambridge, MA 02139
Phone: 617-661-6962
| |
|
|
|
|
Energy & Clean Tech
Life Sciences & Healthcare
Medical Device
|
|
|
Alexandria Venture Investments is the strategic investment entity of Alexandria Real Estate Equities, Inc. (ARE: NYSE). Alexandria Equities provides capital to the broad and diverse life science sector. Since 1994, Alexandria Real Estate has created first-in-class life science clusters that foster innovative and collaborative environments in key locations immediately proximate to leading research institutions. Alexandria's diverse tenant base includes internationally renowned academic and medical institutions, multinational pharmaceutical companies, leading private and public biotechnology entities, non-profit institutions, government agencies, medical device companies, biofuels companies, research tools and service companies, and venture capitalists.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Andres Gavinet | |
| |
Chief Accounting Officer | |
Daniel J. Ryan | |
| |
Co-Chief Investment Officer & Regional Market Director | |
Dean A. Shigenaga | |
| |
Chief Financial Officer & President | |
Joel S. Marcus | |
| |
Executive Chairman & Founder | |
John Cunningham | |
| |
Executive Vice President, Regional Market Director | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/06/2024
|
Nuvig Therapeutics
|
CA
|
$161,000,000
|
Series B
|
11/20/2024
|
Valora Therapeutics
|
CA
|
$30,000,000
|
Seed
|
11/13/2024
|
TRexBio
|
CA
|
$84,000,000
|
Series B
|
11/07/2024
|
Passkey Therapeutics
|
MA
|
$20,000,000
|
Seed
|
10/30/2024
|
Leal Therapeutics
|
MA
|
$45,000,000
|
|
10/23/2024
|
March Biosciences
|
TX
|
$28,400,000
|
Series A
|
10/18/2024
|
Terray Therapeutics
|
CA
|
$120,000,000
|
Series B
|
10/07/2024
|
Judo Bio
|
MA
|
$100,000,000
|
Seed and Series A
|
07/31/2024
|
AIRNA
|
MA
|
$90,000,000
|
Series A
|
05/19/2024
|
Delphia Therapeutics
|
MA
|
$67,000,000
|
Series A
|
05/06/2024
|
OverT Bio
|
NY
|
$16,000,000
|
Seed
|
05/05/2024
|
Clasp Therapeutics
|
MD
|
$150,000,000
|
Series A
|
02/08/2024
|
Neurona Therapeutics
|
CA
|
$120,000,000
|
Venture
|
|
|
|
|
|